<DOC>
	<DOCNO>NCT02586129</DOCNO>
	<brief_summary>Randomized , double-blind , active-controlled , multicenter phase 3 trial evaluate safety efficacy YH14755 subject dyslipidemia Type II Diabetes .</brief_summary>
	<brief_title>Clinical Trial YH14755 Subjects With Dyslipidemia Type II Diabetes</brief_title>
	<detailed_description>This phase 3 trial evaluate safety efficacy YH14755 subject dyslipidemia Type II Diabetes . In YH14755 treatment group , 88 subject assign subject administer YH14755 16 week . In Metformin treatment group , 88 subject assign subject administer Metformin 16 week . In Rosuvastatin treatment group , 88 subject assign subject administer Rosuvastatin 16 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Signed Informed Consent Subjects Dyslipidemia Type II Diabetes 6.5 % ≤ HbA1c level ≤ 9.0 % LDLC level ≤ 250mg/dL ( 6.5 nmal/L ) screen BMI ≤ 45kg/m2 Subjects dose administer diabetes treatment least 4 week prior screen visit . 19 year later , men woman age 75 Pregnant woman , nurse mother subject agree assign contraception study Subject type I Diabetes Subject hypertension control treatment ( blood pressure &gt; 160/110mmHg ) Have know allergy drug Have administer Cyclosporine Have administer Obesity treatment within 12 week prior screen visit Participated clinical trial within 30 day prior first administration Subject judge ineligible investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>